Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Quarterly results Acq. announced Appointed director
|
NITROMED INC (NTMD)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
04/23/2009 |
8-K
| Quarterly results |
04/09/2009 |
8-K
| Form 8-K -- Current report |
03/19/2009 |
8-K
| Form 8-K -- Current report |
02/26/2009 |
8-K
| Form 8-K -- Current report |
01/28/2009 |
8-K
| Form 8-K -- Current report |
01/27/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
01/21/2009 |
8-K
| Form 8-K -- Current report |
01/15/2009 |
8-K
| Form 8-K -- Current report |
01/13/2009 |
8-K
| Other Events, Financial Statements and Exhibits |
12/31/2008 |
8-K
| Form 8-K -- Current report |
12/24/2008 |
8-K
| Form 8-K -- Current report |
12/19/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
12/08/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
11/26/2008 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
11/18/2008 |
8-K
| Asset disposition, Acquisition/merger/asset purchase announced |
10/30/2008 |
8-K/A
| Form 8-K/A -- Current report [amend] |
10/23/2008 |
8-K
| Quarterly results
Docs:
|
"Purchase and Sale Agreement, by and between NitroMed, Inc. and JHP Pharmaceuticals, LLC",
"VOTING AGREEMENT This VOTING AGREEMENT is entered into as of October 22, 2008, by and among NitroMed, Inc., a Delaware corporation , and HealthCare Ventures, Rho Ventures and Invus Public Equities, L.P. and JHP Pharmaceuticals, LLC, a Delaware limited liability company . INTRODUCTION A. Concurrently with the execution and delivery of this Agreement, Seller and Buyer are entering into a Purchase and Sale Agreement pursuant to which, among other things, Seller shall sell, convey, assign, transfer and deliver to Buyer, and Buyer shall purchase and acquire from Seller, all of Seller's right, title and interest in and to all of the Acquired Assets, free and clear of any and all Security Interests, and Buyer shall assume from Seller and be responsible for the Assumed Liabilities. Capitalized ter...",
"NitroMed Announces Agreement to Sell BiDil® Drug Business to JHP Pharmaceuticals, LLC —NTMD Reports Financial Results for Third Fiscal Quarter 2008" |
|
09/17/2008 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
09/10/2008 |
8-K
| Entry into a Material Definitive Agreement |
08/05/2008 |
8-K
| Quarterly results |
06/03/2008 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits |
05/07/2008 |
8-K
| Quarterly results |
03/28/2008 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Other Events, Financi... |
02/29/2008 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
02/14/2008 |
8-K
| Quarterly results
Docs:
|
"NitroMed Reports Financial Results for Fourth Quarter and Full Year 2007 - Conference Call and Webcast Today at 9:00 AM EST- LEXINGTON, MA——NitroMed, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2007. Total revenues for the three months ended December 31, 2007 were $5.0 million compared to $3.5 million for the same period in 2006. BiDil revenues for the fourth quarter were $4.2 million, an increase of $0.7 million, or 21%, over the comparable 2006 period. For the year ended December 31, 2007, the Company reported total revenues of $16.0 million compared to $12.1 million for the same period in 2006, an increase of $3.9 million, or 33%. BiDil accounted for $15.3 million in revenues for the year ended December 31, 2007, representing a $3.2 milli..." |
|
01/17/2008 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Principal Officers; Election of Directors; Appoin...
Docs:
|
"Retention Agreement, between NitroMed, Inc. and Kenneth M. Bate",
"Retention Agreement, between NitroMed, Inc. and James G. Ham, III",
"Retention and Separation Agreement, between NitroMed, Inc. and Jane A. Kramer",
"NitroMed Reports on BiDil XR™ Progress Following FDA Meeting, Announces Restructuring and Suspension of BiDil ® Sales Force, and Retains Investment Bank to Advise on Strategic Options" |
|
10/31/2007 |
8-K
| Quarterly results
Docs:
|
"NitroMed Reports Financial Results for Third Quarter 2007 - Conference Call and Webcast Today at 8:30 AM EDT - LEXINGTON, MA——NitroMed, Inc. , an emerging pharmaceutical company and the maker of BiDil , an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, today reported financial results for its third fiscal quarter and year to date ended September 30, 2007. Total revenues for the three months ended September 30, 2007 were $3.8 million compared to $3.4 million for the same period in 2006, an increase of $0.4 million or 10%. For the nine months ended September 30, 2007, total revenues were $11.0 million, compared to $8.6 million for the same period during 2006, an increase of $2.4 million, or 28%. Sales of BiDil ..." |
|
08/01/2007 |
8-K
| Quarterly results |
05/24/2007 |
8-K
| Other Events, Financial Statements and Exhibits |
05/22/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
05/02/2007 |
8-K
| Quarterly results |
04/04/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
03/22/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
03/14/2007 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits |
|
|
|